Advertisement

Moderna will not bow to China’s coercion, refuses to give COVID-19 vaccine recipe over ‘safety’ concerns

China hasn’t approved any foreign vaccine and has been insisting on sharing the technology behind the Moderna vaccine as a prerequisite for allowing its sale in the country

Advertisement
FP Staff|Oct 02, 2022, 11:11:53 IST

New Delhi: American pharma company Moderna has refused to accept China’s condition to share the technology behind its COIVD-19 vaccine as a prerequisite for approving it citing 'safety' concerns, derailing the negotiations on the sale of the vaccine in China.

Moderna turned down the Chinese government to share with it the recipe for its mRNA vaccine due to commercial and safety reasons, says a Financial Times report quoting sources involved in the negotiations on the sale of the vaccine in China that took place in 2020-2021.

Advertisement

However, the sources added that the company was still ‘eager’ to sell the vaccine in China.

China hasn’t approved any foreign vaccine and has been insisting on sharing the technology behind the Moderna vaccine as a prerequisite for allowing its sale in the country.

Paul Burton, Moderna’s Chief Medical Officer had in September said that the company was “keen” to collaborate with the Chinese government to sell the mRNA vaccine.

worldMore from World

"We would certainly be very eager to collaborate with China if they felt that there was a need for a vaccine there," Burton had said.

"Currently, there is no activity going on”, he said, adding, “but we'd be very open to it."With inputs from agenciesRead all the Latest News, Trending News, Cricket News, Bollywood News,India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Advertisement
Handpicked stories, in your inbox
Global stories. Indian perspective. Zero noise.
No Spam. Unsubscribe Any Time.
First Published:Oct 02, 2022, 10:18:10 IST
Advertisement
Advertisement
Trending Stories

Marco Rubio says he 'would expect India to be concerned' over Trump's pharma tariffs

US Secretary of State Marco Rubio acknowledged India's concerns over Donald Trump's proposed pharmaceutical tariffs, saying Washington is seeking greater domestic manufacturing while remaining engaged with New Delhi.
2 min read
Advertisement
Advertisement
Up Next